Time in the Market, Not Timing the Market: Featured Research on Rite Aid, American Homes 4 Rent, Perfect World, Foamix, and Cesca

NEW YORK, January 5, 2015 /PRNewswire/ --

Moments ago, Analysts Review released new research updates concerning several important developing situations including Rite Aid (NYSE: RAD), American Homes 4 Rent (NYSE: AMH), Perfect World (NASDAQ: PWRD), Foamix (NASDAQ: FOMX), and Cesca (NYSE: KOOL). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.

To access our full PDF reports on a complementary basis, please visit the links below.

--

Today's update concerns the following companies:

============

Full PDF Download Links (you may have to copy and paste the following links into your browser):

RADResearch Report: ( http://get.analystsreview.com/pdf/?c=Rite%20Aid&d=05-Jan-2015&s=RAD ),

AMH Research Report: ( http://get.analystsreview.com/pdf/?c=American%20Homes%204%20Rent&d=05-Jan-2015&s=AMH ),

PWRD Research Report: ( http://get.analystsreview.com/pdf/?c=Perfect%20World&d=05-Jan-2015&s=PWRD ),

FOMX Research Report: ( http://get.analystsreview.com/pdf/?c=Foamix&d=05-Jan-2015&s=FOMX ),

KOOL Research Report: ( http://get.analystsreview.com/pdf/?c=Cesca&d=05-Jan-2015&s=KOOL ).

============

--

Analyst Update: FDA Feedback, Monthly Sales Numbers, Acquisitions, and Corporate Updates 
Reviewed by: Rohit Tuli, CFA®

The US stock market ended Friday's session on a mixed note, following disappointing US manufacturing and construction reports. The Institute for Supply Management manufacturing index declined to 55.5% in December 2014, from 58.7% in November 2014, partly due to labor problems at key West Coast ports. In addition, the US construction spending fell 0.3% in November 2014. The three main US indexes snapped their two-week winning streak. The Dow Jones Industrial Average moved up 0.06%, S&P 500 declined 0.03%, and Nasdaq Composite weakened 0.20% during the session. The European stock market closed mainly in red after eurozone manufacturing data for December 2014 fell short of expectations.  The European stock market started the session on a positive note after European Central Bank President Mario Draghi hinted the bank is moving closer to launching a full-scale quantitative-easing program. The Asian markets ended their first trading session of 2015 on a positive note on low trading volume with the region's two largest markets shut for holidays.

Rite Aid Corporation's (Rite Aid) stock rose 1.46% as the Company reported an improvement in sales.  The Company, which is one of the largest drugstore chains in the US, reported a 5.3% YoY increase in same sales stores for the month of December 2014. A further detailed analysis of the sales report is available in our research report.

Shares of American Homes 4 Rent gained almost 2% after the Company announced it acquired Ellington Housing Single-Family portfolio for approx. $126 million. In a December 31, 2014 press release, the Company said the acquisition involves approximately 900 homes located in markets in Arizona, Colorado, Georgia, North Carolina, Tennessee and Texas. Read our research report on American Homes 4 Rent to know more about the acquisition and how the Company intends to fund it.

ADSs of Chinese online game developer - Perfect World Co. Ltd (Perfect World) rallied 22% after the Company said it has received a 'go-private' bid from its founder and Chairman of the Board, Michael Yufeng Chi. Read more about the details of this non-binding offer and ADSs reaction to the development in our research report on Perfect World.

Shares of Foamix Pharmaceuticals Ltd (Foamix) have made a decisive move and rose above the IPO price of $6.00 in December. On January 2, 2015, the shares of the clinical-stage specialty pharmaceutical Company closed at $7.45. Read our research report on Foamix to know more the Company.

Cesca Therapeutics Inc (Cesca) received FDA feedback highlighting deficiencies in the Company's submission, and asking for more information related to its pivotal Investigational Device Exemption (IDE) application for the treatment of Critical Limb Ischemia (CLI). The FDA, however, has not questioned the overall trial design, Cesca said. Read more about the details FDA has asked for in our research report on Cesca.

--

About Analysts Review  

At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.

--

Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.

Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA®. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED